Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
Abstract Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac functio...
Gespeichert in:
| Veröffentlicht in: | Oxford Medical Case Reports 2017-07, Vol.2017 (7), p.omx038 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | omx038 |
| container_title | Oxford Medical Case Reports |
| container_volume | 2017 |
| creator | Tanaka, Satoru Ikari, Ayana Nitta, Toshikatsu Horiuchi, Tetsuya |
| description | Abstract
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rarely experience chronic heart failure or prolonged left ventricular ejection fraction reduction. There have been no detailed published analyses of patients with such unfavorable clinical courses. We report the rare case of a metastatic breast cancer in a woman without cardiac risk factors who experienced long-term irreversible cardiotoxicity after discontinuation of trastuzumab therapy. |
| doi_str_mv | 10.1093/omcr/omx038 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5499211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/omcr/omx038</oup_id><sourcerecordid>10.1093/omcr/omx038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-b8a856bb7bde11da7ca7295be302201120fb52e07845ea1a33b758b82e6c82263</originalsourceid><addsrcrecordid>eNp9kT1P5DAQhi3E6UDcVtcjVzQo4I84cRokhOAOaSUaro5sZwKGTbwaO3xV_PTzKoCgofGMNI8fW_MS8puzI84aeRwGh_l4YlJvkV3BlCy0Vmr7U79DFjHeMca4rLjU-ifZEbpqyqYud8nrMow3RQIcqEeEB8Do7QpoQhPT9DINxhZ-7CYHHXUGOx9SePLOp2faB6QDpMyZ5B21CLnN0OgAqR-poes8gDHRR59uw5RmgXEUfbynvXEpYPxFfvRmFWHxVvfIv4vz67O_xfLqz-XZ6bJwZalSYbXRqrK2th1w3pnamVo0yoJkQjDOBeutEsBqXSow3Ehpa6WtFlA5LUQl98jJ7F1PdoDO5X-hWbVr9IPB5zYY336djP62vQkPrSqbRnCeBYezwGGIEaH_uMtZu8mi3WTRzllkev_zcx_s--YzcDADYVp_a_oPoCKYkQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Tanaka, Satoru ; Ikari, Ayana ; Nitta, Toshikatsu ; Horiuchi, Tetsuya</creator><creatorcontrib>Tanaka, Satoru ; Ikari, Ayana ; Nitta, Toshikatsu ; Horiuchi, Tetsuya</creatorcontrib><description>Abstract
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rarely experience chronic heart failure or prolonged left ventricular ejection fraction reduction. There have been no detailed published analyses of patients with such unfavorable clinical courses. We report the rare case of a metastatic breast cancer in a woman without cardiac risk factors who experienced long-term irreversible cardiotoxicity after discontinuation of trastuzumab therapy.</description><identifier>ISSN: 2053-8855</identifier><identifier>EISSN: 2053-8855</identifier><identifier>DOI: 10.1093/omcr/omx038</identifier><identifier>PMID: 28694974</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Case Report</subject><ispartof>Oxford Medical Case Reports, 2017-07, Vol.2017 (7), p.omx038</ispartof><rights>The Author 2017. Published by Oxford University Press. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-b8a856bb7bde11da7ca7295be302201120fb52e07845ea1a33b758b82e6c82263</citedby><cites>FETCH-LOGICAL-c445t-b8a856bb7bde11da7ca7295be302201120fb52e07845ea1a33b758b82e6c82263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499211/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499211/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1604,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28694974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Satoru</creatorcontrib><creatorcontrib>Ikari, Ayana</creatorcontrib><creatorcontrib>Nitta, Toshikatsu</creatorcontrib><creatorcontrib>Horiuchi, Tetsuya</creatorcontrib><title>Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors</title><title>Oxford Medical Case Reports</title><addtitle>Oxf Med Case Reports</addtitle><description>Abstract
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rarely experience chronic heart failure or prolonged left ventricular ejection fraction reduction. There have been no detailed published analyses of patients with such unfavorable clinical courses. We report the rare case of a metastatic breast cancer in a woman without cardiac risk factors who experienced long-term irreversible cardiotoxicity after discontinuation of trastuzumab therapy.</description><subject>Case Report</subject><issn>2053-8855</issn><issn>2053-8855</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kT1P5DAQhi3E6UDcVtcjVzQo4I84cRokhOAOaSUaro5sZwKGTbwaO3xV_PTzKoCgofGMNI8fW_MS8puzI84aeRwGh_l4YlJvkV3BlCy0Vmr7U79DFjHeMca4rLjU-ifZEbpqyqYud8nrMow3RQIcqEeEB8Do7QpoQhPT9DINxhZ-7CYHHXUGOx9SePLOp2faB6QDpMyZ5B21CLnN0OgAqR-poes8gDHRR59uw5RmgXEUfbynvXEpYPxFfvRmFWHxVvfIv4vz67O_xfLqz-XZ6bJwZalSYbXRqrK2th1w3pnamVo0yoJkQjDOBeutEsBqXSow3Ehpa6WtFlA5LUQl98jJ7F1PdoDO5X-hWbVr9IPB5zYY336djP62vQkPrSqbRnCeBYezwGGIEaH_uMtZu8mi3WTRzllkev_zcx_s--YzcDADYVp_a_oPoCKYkQ</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Tanaka, Satoru</creator><creator>Ikari, Ayana</creator><creator>Nitta, Toshikatsu</creator><creator>Horiuchi, Tetsuya</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170701</creationdate><title>Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors</title><author>Tanaka, Satoru ; Ikari, Ayana ; Nitta, Toshikatsu ; Horiuchi, Tetsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-b8a856bb7bde11da7ca7295be302201120fb52e07845ea1a33b758b82e6c82263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Satoru</creatorcontrib><creatorcontrib>Ikari, Ayana</creatorcontrib><creatorcontrib>Nitta, Toshikatsu</creatorcontrib><creatorcontrib>Horiuchi, Tetsuya</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxford Medical Case Reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Satoru</au><au>Ikari, Ayana</au><au>Nitta, Toshikatsu</au><au>Horiuchi, Tetsuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors</atitle><jtitle>Oxford Medical Case Reports</jtitle><addtitle>Oxf Med Case Reports</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>2017</volume><issue>7</issue><spage>omx038</spage><pages>omx038-</pages><issn>2053-8855</issn><eissn>2053-8855</eissn><abstract>Abstract
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rarely experience chronic heart failure or prolonged left ventricular ejection fraction reduction. There have been no detailed published analyses of patients with such unfavorable clinical courses. We report the rare case of a metastatic breast cancer in a woman without cardiac risk factors who experienced long-term irreversible cardiotoxicity after discontinuation of trastuzumab therapy.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>28694974</pmid><doi>10.1093/omcr/omx038</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2053-8855 |
| ispartof | Oxford Medical Case Reports, 2017-07, Vol.2017 (7), p.omx038 |
| issn | 2053-8855 2053-8855 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5499211 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Case Report |
| title | Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T05%3A53%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20irreversible%20trastuzumab-induced%20cardiotoxicity%20for%20metastatic%20breast%20cancer%20in%20a%20patient%20without%20cardiac%20risk%20factors&rft.jtitle=Oxford%20Medical%20Case%20Reports&rft.au=Tanaka,%20Satoru&rft.date=2017-07-01&rft.volume=2017&rft.issue=7&rft.spage=omx038&rft.pages=omx038-&rft.issn=2053-8855&rft.eissn=2053-8855&rft_id=info:doi/10.1093/omcr/omx038&rft_dat=%3Coup_pubme%3E10.1093/omcr/omx038%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28694974&rft_oup_id=10.1093/omcr/omx038&rfr_iscdi=true |